pat_auckland said:MASHdoc_SA said: ...but the FDA says semaglutide...
Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.
julia.endo said:Agreed, and ALT falling is not the same as fibrosis improving.
Adding a me-too, because a thread of one person's experience is not much use.
julia.endo said:Agreed, and ALT falling is not the same as fibrosis improving.
Coming at julia.endo’s question from a different direction. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne concrete data point for the thread. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.
Ask again with the specifics and you will get a better answer than this one.
Moderator note: the sourcing question belongs in the vendor section and has been split out. Tagging this one for the weekly digest.